A spinout from UCSF affiliate Gladstone Institutes, Tenaya secured funding from VC firm Column Group to develop cures for heart disease.

PatientPing has added $31.6m to its coffers, a year after GV co-led a $9.6m series A round.

Creabilis has agreed to an acquisition by Sienna Biopharmaceuticals that could exceed $150m in value and provides an exit to AbbVie.

Precision medicine developer Metabolon, whose backers include Sumitomo, will use the additional $15m from Essex Woodlands to buy back shares.

Bill Maris, co-founder of GV who left the unit earlier this summer, is raising a $230m fund that will focus on the healthcare sector.

The life sciences and tech commercialisation company sold 17 million new shares to investors including Woodford, which contributed $19m.

The kidney disease treatment developer secured funding from investors including Baxter Healthcare as it looks to market its products by 2018.